Role of radiation in oligo-progression in EGFR mutated metastatic non small cell lung cancer

被引：0
|
作者：
Rathee, N. [1 ]
Arunsingh, M. [1 ]
Bhattacharyya, T. [1 ]
Majumder, P. [1 ]
Chowdhury, O. [1 ]
Shah, S. [1 ]
机构：
[1] Tata Med Ctr, Kolkata, India
来源：
CLINICAL ONCOLOGY | 2024年 / 36卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HAB035
引用
收藏
页码：E367 / E367
页数：1
相关论文
共 50 条
  • [41] Non-small-cell lung cancer: how to manage EGFR-mutated disease
    Pecci, Federica
    Cantini, Luca
    Metro, Giulio
    Ricciuti, Biagio
    Lamberti, Giuseppe
    Farooqi, Ammad Ahmad
    Berardi, Rossana
    DRUGS IN CONTEXT, 2022, 11
  • [42] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
  • [43] The Response of EGFR-Mutated Non-Small Cell Lung Cancer Spine Metastases to Stereotactic Body Radiation Therapy
    Zhuang, R. H.
    Balagamwala, E. H.
    Reddy, C. A.
    Lee, M. Y.
    Angelov, L.
    Chao, S. T.
    Suh, J. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E450 - E450
  • [44] Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
    Nicole, Princic
    Elizabeth, Marrett
    Jacqueline, Kwong Winghan
    Donna, Mcmorrow
    Hana, Schwartz
    Janakiraman, Subramanian
    FUTURE ONCOLOGY, 2024,
  • [45] Rebiopsy Post Progression in EGFR Mutated Lung Cancer
    Chandrasekharan, Arun
    Patil, Vijay
    Norohna, Vanita
    Joshi, Amit
    Choughale, Anuradha
    Rajeev, Kumar
    Mahajan, Abhishek
    Janu, Amit
    Goud, Supriya
    More, Sucheta
    Karpe, Ashay
    Ramaswamy, Anant
    Pande, Nikhil
    Goel, Alok
    Talreja, Vikas
    Prabhash, Kumar
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1248 - S1249
  • [46] Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer
    Christopoulos, P.
    Bozorgmehr, F.
    Volckmar, A. L.
    Kirchner, M.
    Magios, N.
    Kuon, J.
    Kazdal, D.
    Budczies, J.
    Endris, V
    Bochtler, T.
    Herth, F. J. F.
    Heussel, C. P.
    Winter, H.
    Muley, T.
    Meister, M.
    Rieken, S.
    Faehling, M.
    Bischoff, H.
    Stenzinger, A.
    Thomas, M.
    PNEUMOLOGIE, 2020, 74 : S132 - S132
  • [47] Recurrent EGFR Mutated Non-Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options
    Copur, Mehmet Sitki
    Lackner, Rudy
    Rodriguez, Paul
    Horn, Adam J.
    Faris, Shellie
    Zusag, Thomas
    ONCOLOGY-NEW YORK, 2020, 34 (09): : 347 - 351
  • [48] Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder
    Bersanelli, Melissa
    Bini, Paola
    Rabaiotti, Enrico
    Facchinetti, Francesco
    De Filippo, Massimo
    Bortesi, Beatrice
    Buti, Sebastiano
    Tiseo, Marcello
    TUMORI, 2017, 103 (01) : 66 - 71
  • [49] Metastatic non-small-cell lung cancer with EGFR mutation - case report
    Jasiowka, Marek
    Cedrych, Ida
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G46 - G48
  • [50] Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumour response to anti-PD1 treatment
    Guisier, F.
    Gervais, R.
    El Husseini, K.
    Assie, J-B.
    Geier, M.
    Decroisette, C.
    Corre, R.
    Descourt, R.
    Chouaid, C.
    Salaun, M.
    Thiberville, L.
    ANNALS OF ONCOLOGY, 2019, 30
12345